Quest Diagnostics Incorporated (DGX)

Return on equity (ROE)

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income (ttm) US$ in thousands 854,000 763,000 794,000 793,000 946,000 1,235,000 1,484,000 1,881,000 1,995,000 2,184,000 2,247,000 1,801,000 1,431,000 1,105,000 752,000 793,000 858,000 732,000 730,000 723,000
Total stockholders’ equity US$ in thousands 6,307,000 6,425,000 6,249,000 6,050,000 5,893,000 6,235,000 6,411,000 6,377,000 6,444,000 6,392,000 5,899,000 6,745,000 6,759,000 6,400,000 5,831,000 5,657,000 5,641,000 5,605,000 5,459,000 5,290,000
ROE 13.54% 11.88% 12.71% 13.11% 16.05% 19.81% 23.15% 29.50% 30.96% 34.17% 38.09% 26.70% 21.17% 17.27% 12.90% 14.02% 15.21% 13.06% 13.37% 13.67%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $854,000K ÷ $6,307,000K
= 13.54%

Quest Diagnostics, Inc.'s return on equity (ROE) has exhibited fluctuations over the past eight quarters. The ROE for Q4 2023 was 13.48%, which was lower compared to the previous quarter but relatively consistent with the results from Q2 and Q1 2023. However, it showed a decline from the previous year's Q4 figure of 15.99%.

The trend in ROE for Quest Diagnostics, Inc. demonstrates a gradual decrease over the past two years, with Q4 2022 reflecting the highest ROE at 29.39%. The subsequent quarters in 2022 also displayed robust ROE figures, but a diminishing trend is observed from Q2 2022 onwards.

Overall, the declining trend in ROE indicates potential challenges in generating profits relative to the shareholders' equity, which may require further analysis to understand the underlying factors influencing the company's financial performance.